Revvity, Inc.
Health
Performance
4.5
Risk
Sell
Buy
Curious about the Scores? Learn more.

Revvity, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

16.07.2026
On shaky ground. Struggling to find a clear direction.
14.07.2026
Risk creeping up. Stability not bulletproof anymore.
13.07.2026
Slight bounce. Could be noise – or a comeback brewing.
01.07.2026
Stability slipping. Financial grip’s not as firm as it was.
RVTY
Revvity, Inc.
110.49
+3.80%
4.5
Sell
Buy
Revvity, Inc.

Revvity, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Revvity, Inc. do? Business model and key facts

Get the full picture of Revvity, Inc.: what it builds, where it operates, and how it makes money.

Revvity, Inc. Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 11000

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

shop
Company facts
Prahlad R. Singh
CEO
11000
Employees worldwide
shop
Performance
17.33%
Last 12 months
-31.5%
Last 5 years
shop
Growth
$2.86B
Revenue year
$241.20M
Net income
shop
Valuation
$12.29B
Market Cap
46.69
Price/Earnings Ratio

Stocks related to Revvity, Inc.

Selected based on industry alignment and relative market positioning.

ICLR
ICON Public Limited Company
166.62
+0.26%
7.7
Sell
Buy
ICON Public Limited Company
MEDP
Medpace Holdings, Inc.
531.67
+0.71%
5.6
Sell
Buy
Medpace Holdings, Inc.
EXAS
Exact Sciences Corporation
104.91
+0.00%
5.9
Sell
Buy
Exact Sciences Corporation
CRL
Charles River Laboratories International, Inc.
219.42
-0.13%
5.6
Sell
Buy
Charles River Laboratories International, Inc.
QGEN
Qiagen N.V.
40.52
+0.09%
5.3
Sell
Buy
Qiagen N.V.

Events and news impacting Revvity, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Revvity, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.